Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick N Harter

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
EMBO Molecular Medicine|December 16, 2015
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastomaAlexander Scholz, Patrick N Harter, Sebastian Cremer, et al.
Acta Neuropathologica|October 18, 2021
Genetic and epigenetic characterization of posterior pituitary tumorsSimone Schmid, David A Solomon, Eilis Perez, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune Checkpoint Sensitivity in BRAFV600E -mutant GliomaYao Lulu Xing, Dena Panovska, Jong-Whi Park, et al.
Cell Reports. Medicine|June 12, 2025
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF<sup>V600E</sup>-mutant gliomaYao Lulu Xing, Dena Panovska, Jong-Whi Park, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2025
Clinical potential of [<sup>18</sup>F]FET PET in patients with circumscribed astrocytic gliomaJan-Michael Werner, Maximilian J Mair, Michael M Wollring, et al.
Acta Neuropathologica|April 25, 2026
Loss of meningothelial identity and mesenchymal fate switching in NF2-mutant meningiomasRamin Rahmanzade, Leonille Schweizer, Simone Schmid, et al.
Neuro-Oncology|November 1, 2020
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFRPhilipp Sievers, Martin Sill, Daniel Schrimpf, et al.
Neuro-Oncology|June 12, 2016
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activationEskil Eskilsson, Gro V Rosland, Krishna M Talasila, et al.
Acta Neuropathologica|August 16, 2019
MYCN amplification drives an aggressive form of spinal ependymomaDavid R Ghasemi, Martin Sill, Konstantin Okonechnikov, et al.
Neuro-Oncology|May 6, 2023
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastomaMichael C Burger, Marie-Therese Forster, Annette Romanski, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
EMBO Molecular Medicine|December 16, 2015
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastomaAlexander Scholz, Patrick N Harter, Sebastian Cremer, et al.
Acta Neuropathologica|October 18, 2021
Genetic and epigenetic characterization of posterior pituitary tumorsSimone Schmid, David A Solomon, Eilis Perez, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune Checkpoint Sensitivity in BRAFV600E -mutant GliomaYao Lulu Xing, Dena Panovska, Jong-Whi Park, et al.
Cell Reports. Medicine|June 12, 2025
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF<sup>V600E</sup>-mutant gliomaYao Lulu Xing, Dena Panovska, Jong-Whi Park, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2025
Clinical potential of [<sup>18</sup>F]FET PET in patients with circumscribed astrocytic gliomaJan-Michael Werner, Maximilian J Mair, Michael M Wollring, et al.
Acta Neuropathologica|April 25, 2026
Loss of meningothelial identity and mesenchymal fate switching in NF2-mutant meningiomasRamin Rahmanzade, Leonille Schweizer, Simone Schmid, et al.
Neuro-Oncology|November 1, 2020
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFRPhilipp Sievers, Martin Sill, Daniel Schrimpf, et al.
Neuro-Oncology|June 12, 2016
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activationEskil Eskilsson, Gro V Rosland, Krishna M Talasila, et al.
Acta Neuropathologica|August 16, 2019
MYCN amplification drives an aggressive form of spinal ependymomaDavid R Ghasemi, Martin Sill, Konstantin Okonechnikov, et al.
Neuro-Oncology|May 6, 2023
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastomaMichael C Burger, Marie-Therese Forster, Annette Romanski, et al.
Pageof 21